2015 Archived Content
Dinner Short Course: Funding Opportunities for Antibacterial Research*
5:30-8:30 pm, November 17
Melissa Stundick, Ph.D., Chief, Anti-infectives Program, BARDA
Randall L. Kincaid, Ph.D., Senior Scientific Officer, Concept Acceleration Program, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH
The course will cover:
- From basic research to the clinic – how do we support the discovery & development of new agents?
- Grants, contracts and biodefense partnerships
- Preclinical, nonclinical, and clinical product development services
Melissa Stundick, Ph.D., is the Anti-infectives Program Chief within the Biomedical Advanced Research and Development Authority (BARDA) at the Department of Health and Human Services (DHHS). She oversees a portfolio of contracts which support the procurement or advanced research and development of the following therapeutics: novel antibacterials, smallpox antivirals, antitoxins, and ebola therapeutics. Prior to joining BARDA in 2011, Dr. Stundick provided scientific and program management support as a Contractor to a number of Government and private entities, including the Department of Defense, Department of Homeland Security, National Center for Medical Intelligence (NMCI), and the Bill and Melinda Gates Foundation. She received her PhD from the Johns Hopkins School of Medicine and her B.S. in Chemistry from Bates College. She also holds a Certificate of Intelligence Analysis from the University of Maryland.
Randall Kincaid, Ph.D., is a Senior Scientific Officer in the Division of Microbiology and Infectious Diseases within the National Institute of Allergy and Infectious Disease. As part of the Concept Acceleration Program, he provides guidance on translational research opportunities which address the needs of infectious disease with a particular focus on platform technologies and diagnostics. He currently is a member of several U.S. Government interagency advisory groups, including the PHEMCE Integrated Product Team (IPT) on Diagnostics and Antimicrobial Resistance IPT. He serves on FDA’s MCMI Regulatory Sciences Steering Committee and previously has been on advisory committees to CDC and DHS in areas of pathogen surveillance and biological threat detection. Prior to his current position, Dr. Kincaid held Chief Scientist and Scientific Director positions in major biodefense programs in the Department of Defense. He has also held positions in industry – as Director of Cell Biology at Human Genome Sciences and as CEO and President of his own company, Veritas, for 14 years – in addition to being a consultant to several enterprises. Dr. Kincaid was a tenured investigator at the NIH from 1977-1993, during which time he built a research program that studied intracellular signaling mechanisms and their relationship to immune cell activation and neuronal function; those efforts resulted in > 80 publications. He was an Editorial Board member for the Journal of Biological Chemistry for six years and held adjunct professor appointments at Penn State and George Washington Universities. He received both his undergraduate and graduate degrees from Stanford University where he continues to maintain strong academic and personal relationships.
*Separate Registration Required